Endonovo Therapeutics Files Continuation Patent for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome

LOS ANGELES, CA--(Marketwired - Jun 29, 2016) - Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) ("Endonovo" or the "Company"), a developer of bioelectronic devices and medicines, announced today that it has filed a continuation patent, titled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Endonovo's patent filing covers a process for the production of the adult stem cell secretome and its corresponding administration as a next generation fully human biologic.

This patent filing is a continuation of the prior announcement on March 30, 2016.

Adult stem cells, such as Mesenchymal Stem Cells ("MSCs") isolated from tissues, including bone marrow and the human umbilical cord release a plethora of cytokines, interleukins, prostaglandins, and growth factors, referred to collectively as the secretome.

Many studies have ascertained and continue to clarify that the therapeutic potential of adult stem cells is linked to their ability to secrete therapeutic proteins and other molecules. However, human cells typically secrete very low concentrations of these therapeutic cytokines and growth factors and have required the use of recombinant DNA technology to develop them as biologics.

According to Thomson Reuters, the biologics sector is set for an unprecedented level of activity as U.S. companies have rapidly increased their development of biologics during the past five years. The market for next-generation biologics is estimated to reach a value of $30 billion by 2024, according to Visiongain . These next-generation biologics will seek to address shortcomings in current therapies, including inconvenient dosing and potential side-effects.

Endonovo CEO, Alan Collier commented, "We are largely looking at adult stem cells as tiny drug factories capable of producing the most complex and hard to produce drugs known as biologics."

Mr. Collier went on to say, "One of the benefits of our approach in using the secretome as a next generation fully human biologic is that it is much easier to manufacture than conventional biologics manufactured by synthetic or recombinant DNA technology, which could result in better outcomes for patients and lower costs."

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact: Endonovo Therapeutics, Inc. Mr. Steven Barnes Senior Vice President of Investor Relations (800) 701-1223, Ext. 108 Sbarnes@endonovo.com www.endonovo.com Source: Endonovo Therapeutics, Inc. Investors: Sign Up for Email Alerts on Endonovo

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 244

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 385

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 273

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 430

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

HUB Cyber Security's Roadmap for Revolutionary Financial Solutions

Updated Category News Views 164

HUB Cyber Security Unveils Revolutionary Financial Solutions HUB Cyber Security Ltd. (Nasdaq: HUBC) has shared an ambitious roadmap to launch the HUB Token (HUBT), positioning itself as a pioneer in the rapidly evolving digital finance landscape. This strategic initiative aims to power the innovative Trvsthub™ platform, which promises to enhance the security and...

Continue Reading
MSU Energy Completes Successful Exchange Offer for Senior Notes

Updated Category News Views 227

MSU Energy Completes Successful Exchange of Senior Notes MSU Energy S.A. has announced the results of its recent exchange offer, which culminated successfully within an established timeframe. This initiative involved an exchange for up to $218,973,000 in aggregate principal amount of its existing 6.875% Senior Notes due 2025. The transition to new financial instruments...

Continue Reading
Major Defense Contracts Awarded to Lockheed and Boeing

Updated Category News Views 304

The Pentagon's New Contracts The recent contracts awarded by the Pentagon to Lockheed Martin Corporation (NYSE: LMT) and Boeing Company (NYSE: BA) exemplify the ongoing investment in national defense. These new agreements underscore a robust financial commitment to enhancing military capabilities. Lockheed Martin's Taiwan FMS Award Lockheed Martin has secured a pivotal...

Continue Reading
Maryland Army National Guard's General Birckhead to Address Graduates

Updated Category News Views 134

General Janeen L. Birckhead to Inspire Graduates at HCC Columbia, MD — A significant moment is approaching for over 1,100 graduates of Howard Community College (HCC) as they prepare to celebrate their accomplishments at the upcoming commencement exercises. The keynote speaker for this year's ceremony is none other than Major General Janeen L. Birckhead, Adjutant General...

Continue Reading
SUNation Energy Announces Participation in Annual Roth Conference

Updated Category News Views 133

SUNation Energy to Engage in Investment Discussions SUNation Energy, Inc. (Nasdaq: SUNE), a prominent provider of solar energy and power solutions, has made it's presence known as it prepares to take part in a significant investor conference. The upcoming event, known as the Annual Roth Conference, serves as a pivotal platform where growth companies showcase their...

Continue Reading